	US 12,188,050 B2
	Kidney organoids and methods of manufacturing
Melissa Little, Parkville (AU); and Santhosh V. Kumar, Parkville (AU)
Assigned to MURDOCH CHILDRENS RESEARCH INSTITUTE, (AU)
Appl. No. 16/759,642
Filed by MURDOCH CHILDRENS RESEARCH INSTITUTE, Parkville (AU)
PCT Filed Oct. 31, 2018, PCT No. PCT/AU2018/051178 § 371(c)(1), (2) Date Apr. 27, 2020, PCT Pub. No. WO2019/084612, PCT Pub. Date May 9, 2019.
Claims priority of application No. 2017904424 (AU), filed on Oct. 31, 2017.
Prior Publication US 2020/0291361 A1, Sep. 17, 2020
Int. Cl. C12N 5/071 (2010.01); A61K 35/22 (2015.01); A61L 27/38 (2006.01); B33Y 70/00 (2020.01); G01N 33/50 (2006.01)

CPC C12N 5/0686 (2013.01) [A61K 35/22 (2013.01); A61L 27/3804 (2013.01); B33Y 70/00 (2014.12); G01N 33/5014 (2013.01); A61L 2430/26 (2013.01); C12N 2501/119 (2013.01); C12N 2501/415 (2013.01); C12N 2506/45 (2013.01); C12N 2513/00 (2013.01); C12N 2533/30 (2013.01)]

17 Claims

1. An in-vitro method of producing a kidney organoid, the method comprising, swirling a population of dissociated intermediate mesoderm (IM) cells in a cell culture medium comprising fibroblast growth factor (FGF), wherein the kidney organoid comprises NPHS1+ podocytes, LTL+ proximal segments, ECAD+distal segments and ECAD+/GATA3+ collecting ducts, wherein the IM cells are swirled in culture for at least 5 days, wherein the first 24 hours comprise swirling cells in a cell culture medium comprising FGF, heparin, CHIR99021 (CHIR) and rho-associated protein kinase (ROCK) inhibitor.